Command Palette

Search for a command to run...

WALPAR
40.55(+0.00%)
1W: -1.22%

Peers

Snapshot Summary

Walpar Nutritions Ltd. demonstrates impressive growth metrics, particularly in revenue and earnings, positioning it favorably compared to its peers. However, its valuation ratios suggest caution, as the company is still in the early stages of profitability. While several peers exhibit strong performance, some are overvalued based on their earnings potential, making Walpar a potential value pick within the sector.

  • Walpar shows the highest revenue growth (YoY) at 77.91%.
  • Cipla leads in profitability with the highest ROE of 16.63%.
  • Sun Pharma has the highest PE ratio at 87.59, indicating overvaluation.
  • Divi's Labs shows concerning revenue declines over 3 years, highlighting potential instability.
  • Cipla Ltd.: Highest ROE of 16.63%, indicating effective management and strong profitability.
  • Dr. Reddy's Laboratories Ltd.: Consistently strong growth with a solid balance sheet and good margins.
  • Mankind Pharma Ltd.: Excellent revenue growth (YoY) with high profitability ratios.
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
WALPAR--0.0014.23%0.59
SUNPHARMA₹1,563.35₹3,75,099.26Cr87.5917.60%0.04
DIVISLAB₹6,091.05₹1,61,698.50Cr73.2016.46%-
CIPLA₹1,587.60₹1,28,217.27Cr23.7322.77%0.01
TORNTPHARM₹3,581.55₹1,21,215.77Cr61.5324.28%0.57
DRREDDY₹1,280.30₹1,06,835.27Cr15.5026.86%0.07
MANKIND₹2,518.95₹1,03,926.59Cr55.1828.38%0.02